

Risk Factors and Mechanism of Hemorrhagic Transformation of Acute Ischemic Cerebral Infarction

ABSTRACT

A feared complication of ischemic cerebrovascular accident (CVA) is hemorrhagic transformation and it increases the length of hospital admissions, results in poor clinical outcomes and increases mortality. This study aims to identify risk factors of hemorrhagic transformation, discuss the pathogenesis of transformation and prognosis of the condition from original studies conducted within the past 10 years. PubMed and EMBASE are the major databases used. Eight articles met the inclusion criteria and are a mixture of retrospective and prospective studies. The sample size ranges from 32 to 1484 patients. Generally, the mechanism of hemorrhagic transformation identified involves the release of reactive oxygen species and metalloproteinase as a result of cerebral ischemia. Metalloproteinase further causes a breakdown of the extracellular matrix, thereby giving rise to the extravasation of cellular components. Some identified risk factors include: age, use of antithrombotic, the subtype of ischemic stroke, the severity of stroke and hypertension. Prognosis is linked to the type of hemorrhagic infarctions according to the European Cooperative Acute Stroke Study II (ECASS II) with patients with either hemorrhagic infarct type 2 (HI2) and parenchymal hematoma type 2 (PH2) having the worst functional outcome.

Keywords: [Hemorrhagic transformation; Acute ischemic cerebral infarction; Cerebrovascular accident; Risk factors]

1. INTRODUCTION

Acute Ischemic Stroke (AIS) accounts for over 60% of cerebrovascular accidents, which is still a leading cause of mortality in the US and globally [1, 2]. In the US alone, the incidence rate of stroke is 795 000 per year, with an estimated mortality of 1 in every 19 deaths as of 2018 [1]. Although there has been a general decrease in trends for age-standardized rates in the last three decades due to improved quality of care and health, for the most part, its socioeconomic impact cannot be ignored [3, 4].

Hemorrhagic transformation (HT) is one of the interesting phenomena in the series of biochemical events that occur following AIS. It is found in approximately 3-40% of AIS and it is thought to be associated with worsening neurological outcomes [5]. HT is the first sign of hemorrhage immediately after an ischemic event typically occurring within 2 weeks, however, it can be detected radiologically as a hypodense area as early as 5 hours post AIS [6]. "It can be classified according to the European Cooperative Acute Stroke Study II (ECASS II)" [7], as follows;

1. Hemorrhagic infarction type 1 (HI1) - Petechial hemorrhages at the infarct margins.
2. Hemorrhagic infarct type 2 (HI2) - Petechial hemorrhages throughout the infarct.
3. Parenchymal hematoma type 1 (PH1) - <30% of the infarcted area with slight space occupying effect.

31 4. Parenchymal hematoma type 2 (PH2) - >30% of infarct zone with significant space
32 occupying effect due to hematoma.

33 AIS can occur secondary to underlying haematological conditions such as polycythemia
34 vera, sickle cell disease, and essential thrombocythemia. These account for 1.3% of all
35 causes of acute stroke [8]. In addition to current public health measures addressing the
36 modifiable risk factors, improved scoring systems and stroke care, more research is needed
37 for the better understanding of the risk factors and the mechanism of transformation to
38 prevent and improve outcomes. In this review, we will focus on the risk factors for
39 hemorrhagic transformation (HT), mechanism of transformation and its prognosis from
40 original studies conducted within the past 10 years.

41 **2. METHODOLOGY**

42 **2.1 Search Strategy**

43 Using specified search terms, EMBASE and PubMed (MEDLINE), we searched two major
44 databases. Search terms used on the Medline database are "Hemorrhagic Transformation
45 Of Cerebrovascular Accident"[Mesh] OR "Hemorrhagic Transformation Of Stroke"[Mesh]
46 And "Risk Factors" [Mesh]. These terms were combined using the Boolean operators (AND,
47 OR). The search terms used for EMBASE are Hemorrhagic transformation and ischemic
48 cerebrovascular disease.

49 **2.2 Study Selection**

50 Studies were selected according to the criteria:

51 1. Population: Studies focusing on patients with hemorrhagic transformation of
52 ischemic cerebrovascular accidents.

53 2. Exposure: The risk factors that can result in hemorrhagic transformation in people
54 with ischemic cerebrovascular accidents.

55 3. Condition or outcome(s) of interest: The primary outcome is to determine the risk
56 factors of hemorrhagic transformation of ischemic cerebrovascular accidents. The
57 secondary outcome is to explore the mechanism of transforming an ischemic
58 cerebrovascular accident into a hemorrhagic cerebrovascular accident.

59 4. Study design and context: Eligible studies are observational studies and clinical
60 trials.

61 **2.3 Inclusion Criteria:**

62 1. All articles written in English.

63 2. Articles related to the objectives of the study.

64 3. Original studies.

65 4. Articles that met the above criteria and are within the past 10 years (2012-2022).

66 **2.4 Exclusion Criteria:**

- 67 1. Not original studies (e.g. review, systematic review, and commentary articles)
- 68 2. Articles not written in English.
- 69 3. Articles not related to the objectives of the study
- 70 4. Articles more than 10 years.

71 **2.5 Data Collection and Study Assessment**

72 Four authors (AO, GA, AU, and CC) independently reviewed the abstracts of all the articles
 73 identified. Articles adopted were based on the inclusion criteria. The adopted papers were
 74 screened, and a spreadsheet was created to include all the proposed articles to be used for
 75 this study. All authors were involved in the final selection process.

76 **2.6 Data Synthesis**

77 This was done in a clear and detailed descriptive summary of the studies, including using a
 78 summary table. All authors were responsible for reviewing and discussing major identified
 79 themes in the study.

80 **3. RESULTS**

81 After applying the inclusion & exclusion criteria, eight articles were eligible to be included in
 82 the review (see Table 1). Out of the eight articles reviewed, there were two prospective
 83 studies [8,9], five retrospective studies [6,10–13], and one was both a prospective and
 84 retrospective study [14]. The studies were carried out in various countries, such as the China
 85 [9,11–14], United States [13], United Kingdom [10], Germany [10], Italy [8], and the Republic
 86 of Korea [6]. The sample size of the participants ranged from 32 patients to 1484 patients.
 87 The studies were conducted on both genders. The eight articles reviewed discussed the risk
 88 factors of acute ischemic stroke while four articles described the pathogenesis/mechanism of
 89 transformation.

90 **Table 1: Summary of the characteristics of included articles**

Author/year	Title	Country	Study design	Study Population/ Sample size	Risk Factors	Pathogenesis/Mechanism of Transformation
1. Hirata Y et al, 2021	Cerebral Microbleeds With Atrial Fibrillation After Ablation Therapy	China	Prospective study	68 patients	Catheter ablation in patients with atrial fibrillation is at higher risk of developing cerebral microbleeds.	NA
2. Kim et al, 2021	Short-term glycemic variability and	Republic of Korea	Retrospective	169 patients were included in	Time-related glycemic variation (GV)	1. Dysglycemia causes an increased damage

	hemorrhagic transformation after successful endovascular thrombectomy		study	the final analysis- 28 patients had a definite atrial fibrillation, 30 patients had probable atrial fibrillation, 111 patients had no atrial fibrillation.	during the first 36 h after successful endovascular recanalization therapy has a stronger correlation with symptomatic intracranial hemorrhage (ICH) and poor functional outcomes compared to any GV parameters. This suggests that maintaining stable glucose may be an important factor in the prevention of ICH after undergoing successful endovascular thrombotomy.	to blood brain barrier (BBB), thereby increasing the risk of HF and aggravates the degree of hemorrhage after reperfusion. 2. Fluctuating glucose has a more deleterious effect on endothelial function and oxidative stress in the brain tissues compared to constantly elevated glucose levels, which gives rise to metabolic dysregulation and secondary brain injury by accelerating microvascular injury.
3. Wei et al, 2021	Development and Validation of a Predictive Model for Spontaneous Hemorrhagic Transformation After Ischemic Stroke	China	Retrospective & Prospective study	Retrospective cohort: 245 patients Prospective cohort 1: 539 patients Prospective cohort 2: 200 patients	1.Age 2. History of diabetes mellitus and atrial fibrillation 3. High NIHSS score 4. Hypertension 5. hypodensity greater than one-third of the middle cerebral artery territory 6. Midline shift 7. hyper dense artery sign	Di 1. BBB disruption is the primary pathophysiology of HT. Reactive oxygen species and matrix metalloproteinases are activated by cerebral ischemia, reperfusion damage, neuroinflammation, and vascular remodeling, which are the typical molecular processes underlying HT. 2. After receiving reperfusion

treatment, HT might develop according to a few distinct causes. The direct toxicity of alteplase and alteplase-associated coagulopathy may accelerate HT following intravenous thrombolysis.

4. Lin et al, 2021	Fibrinogen Level Combined With Platelet Count for Predicting Hemorrhagic Transformation in Acute Ischemic Stroke Patients Treated With Mechanical Thrombectomy	China	Retrospective study	135 acute ischemic stroke (AIS) patients who had undergone mechanical thrombectomy (MT) And recanalization within 24 hours of symptom onset	Lo1. Lower baseline fibrinogen levels and platelet counts were associated with HT in AIS patients with anterior circulation large-vessel occlusion after MT. 2. The risk of HT after MT can be predicted by a fibrinogen level less than 2.165g/L with a platelet count of less than 171.5 x 10 ⁹ /L.	NA
5. Yuan S et al, 2021	Serum Occludin Level Combined with NIHSS Score Predicts Hemorrhage Transformation in Ischemic Stroke Patients With Reperfusion	China, United States	Retrospective study	76 patients	In this study, it was found that the indicator of BBB damage (serum occludin) and stroke severity (baseline NIHSS score) were independent risk factors of	NA

					HT using multivariate regression analysis	
6. D'Anna et al, 2021	L Extent of white matter lesion is associated with early hemorrhagic transformation in acute ischemic stroke related to atrial fibrillation	United Kingdom, Germany	Retrospective study	441 patients were included in the analysis.	1. Age 2. Presence of large infarct 3. Use of anticoagulants before the stroke 4. Severe neurologic deficit 5. Congestive heart failure 6. Hyperglycemia 7. Renal impairment 8. Low platelet count 9. Elevated systolic blood pressure 10. Use of reperfusion therapies	NA
7. Ruan Y et al, 2021	L High fibrinogen-to-albumin ratio is associated with hemorrhagic transformation in acute ischemic stroke patients	China	Retrospective study	256 HT patients and 256 non-HT patients with AIS	High fibrinogen-to-albumin ratio (FAR)	Inflammation has been considered as an important cause of the blood-brain barrier (BBB) disruption, which may directly lead to HT. It suggested that FAR level is positively correlated with HT and high FAR was independently associated with the

increased risk of HT.

8. Inzitari D et al, 2013	MMP9 Variation After Thrombolysis Is Associated With Hemorrhagic Transformation of Lesion and Death	Italy	Prospective study	327 patients with acute ischemic stroke. (mean age, 68.9±12.1)	Increased level of MMP9.	Tissue-type plasminogen activator (tPA) may enhance expression and activity of MMPs, particularly matrix metalloproteinase-9 (MMP9). MMP antagonists administered to animals treated with tPA lower the risk of HT and reduce infarct volume.
---------------------------	---	-------	-------------------	--	--------------------------	---

91 *NA = Not applicable

92 **4. DISCUSSION**

93 **4.1 Risk Factors and Mechanisms of Hemorrhagic Transformation**

94 **4.1.1 Age**

95 “The majority of studies on age as a risk factor for HT are focused on patients who have had
96 a stroke and have received fibrinolytic therapy” [10,14,15]. “A meta-analysis of 55 studies
97 identified older age as a factor associated with an increased risk of post-alteplase
98 intracerebral hemorrhage” [16]. “The association with age is also consistent with other
99 studies showing that individuals over the age of 80 who receive intravenous tPA may be at
100 increased bleeding risk” [10,14,15,17,18].

101 **4.1.2 Serum Biomarkers**

102 **4.1.2.1 Matrix Metalloproteinases:** They are zinc-binding proteolytic enzymes which
103 remodel the extracellular matrix [19]. The metalloproteinases 2 and 9 as well as leukocytes
104 are released from the vascular endothelium [8,19]. Cerebral ischemia triggering
105 neuroinflammation and vascular remodeling causes activation of reactive oxygen species
106 and matrix metalloproteinases [8]. The Metalloproteinases attacks fibronectin, collagen type
107 IV and laminin, causing a breakdown of the extracellular matrix and this allows extravasation
108 of plasma and cellular components [8,19].

109 **4.1.2.2 Fibrinogen:** It is an important component in the coagulation cascade and thus a
110 biomarker for bleeding [20]. “In conditions of coagulation or fibrinolytic disorders, bleeding is
111 likely to occur. Lin et al discovered that lower baseline fibrinogen levels was associated with
112 an elevated risk of HT after mechanical thrombolysis, they also demonstrated the
113 independent effects of reduced fibrinogen levels on hemorrhagic complications of acute
114 ischemic stroke” [11]. Wang et al described that “fibrinogen less than 1.50g/L was a risk

115 factor for hemorrhagic transformation after thrombolysis” [21]. Yan et al also found that “early
116 decrease in fibrinogen levels was associated with symptomatic intracranial hemorrhage after
117 reperfusion therapy with thrombolysis, with or without endovascular thrombectomy” [22].

118 **4.1.2.3 Albumin:** It has an inverse relationship to the development of early onset
119 neurological complications [12]. Albumin has anti-inflammatory, anti-oxidative and anti-
120 apoptotic properties and is known to predict endothelial dysfunction which is the major
121 mechanism in hemorrhagic transformation [12]. Albuminuria has been seen to be associated
122 with increased risk of HT in patients with acute ischemic stroke [23], as the presence of
123 albuminuria in the first urine sample gotten from patients with acute ischemic stroke has
124 shown to be an independent risk factor for hemorrhagic transformation of cerebral infarction
125 [23]. Rodriguez-Yanez et al demonstrated that “albuminuria increases the risk of
126 hemorrhagic transformation by eightfold and the degree of albuminuria was associated with
127 the severity of hemorrhagic transformation” [23].

128

129 **4.1.3 Hyperglycemia**

130

131 Dysglycemia and increased glycemic variability has been linked to increased risk of
132 transformation of ischemic cerebrovascular accidents. This is due to increased inflammation
133 from release of pro-inflammatory cytokines, apoptosis and cytotoxic oedema [6,10] .
134 Hyperglycemia in patients with acute ischemic stroke has been associated with the risk of
135 HT after intravenous treatment with alteplase [24] as well as after intra-arterial treatment with
136 prourokinase [25]. A report from the Canadian Alteplase for Stroke Effectiveness Study
137 (CASES) [26] documented persistent hyperglycemia at baseline and at 24 hour as the
138 strongest predictor of symptomatic intracerebral hemorrhage [27]. The detrimental effects of
139 hyperglycemia in the setting of acute ischemic stroke are thought to be due to a pro-
140 oxidative, pro-inflammatory, and procoagulant state induced by elevated blood glucose [23].
141 Fluctuating blood glucose is more deleterious than persistently elevated glucose due to
142 metabolic dysregulation and worsening microvascular injury [6].

143

144 **4.1.4 Antithrombotic (antiplatelets and anticoagulants)**

145 When starting antithrombotic medication after an ischemic stroke, it is critical to identify
146 patients who are at risk for even asymptomatic spontaneous HT. As antithrombotics (either
147 antiplatelets or anticoagulants) might cause silent hemorrhages to expand and lead to
148 neurological deterioration, recording the existence and type of HT on imaging has crucial
149 therapeutic implications for when to start these secondary preventive therapies [28].

150 **4.1.4.1 Antiplatelet agents:** In a trial of intra-arterial thrombolysis with prourokinase, aspirin
151 usage was linked to a slight increase in the frequency of HT in patients undergoing
152 thrombolytic treatment [25,29]. “In the National Institute of Neurological Disorders and Stroke
153 NINDS rt-PA trial, the use of antiplatelet medications (mainly aspirin) was not related to an
154 increase in the frequency of symptomatic intracerebral hemorrhages in individuals treated
155 with intravenous alteplase” [30].

156 According to studies, using aspirin and clopidogrel together before a stroke increases the
157 incidence of symptomatic intracerebral hemorrhage after receiving intravenous alteplase
158 [27,31]. “In the SITS-ISTR (Safe Implementation of Thrombolysis in Stroke–International
159 Stroke Thrombolysis Register) research, the aspirin–clopidogrel combination was found to
160 have a higher rate of symptomatic intracerebral hemorrhage (13.4%) than either treatment
161 alone” [31].

162 **4.1.4.2 Anticoagulants:** “The use of oral anticoagulants significantly increased the risk of
163 symptomatic intracerebral hemorrhage in a meta-analysis of clinical trials, which assessed

164 the efficacy and safety of anticoagulant treatment in acute cardio embolic stroke, whereas
165 the rates of death and disability were similar to those of other antithrombotic treatments” [32]
166 . “Because the use of oral anticoagulants is linked to an increased risk of symptomatic
167 intracerebral hemorrhage, particularly in the presence of large infarcts, the administration of
168 oral anticoagulants after a brain infarction should be delayed for several days [32] in the
169 hopes of promoting the stabilization of the blood-brain barrier and reducing the risk of
170 delayed HT” [32].

171 **4.1.5 Ischemic Stroke Subtypes**

172 According to the TOAST criteria [33], ischemic stroke subtypes were classified as
173 cardioembolic, atherothrombotic, small vessel occlusion, and cryptogenic. Cardioembolic
174 stroke has been associated with the highest frequency of HT among the subtypes of
175 ischemic stroke, with 5% of embolic strokes show hemorrhagic infarction on an early
176 Computerized Tomography, and an additional 10% become hemorrhagic after several days
177 [34]. This tendency for HT is increased when cardioembolism causes substantial arterial
178 occlusion and collateral flow failure. HT is exceptionally rare in cases of small vessel
179 occlusion and lacunar stroke [32] .

180 **4.1.6 Recanalization of Occluded Arteries**

181 “Spontaneous or thrombolysis-induced recanalization of main stem cerebral arteries within a
182 few hours after acute ischemic stroke may lead to a good clinical outcome [35]. However,
183 the beneficial effect obtained by thrombolysis-induced recanalization may be counteracted
184 by an increased risk of hemorrhagic transformation (HT)” [35] . Molina et al., reported that
185 “delayed recanalization occurring 6 hours after symptom onset, independently predicts HT in
186 patients with acute cardioembolic stroke” [35]. “They also reported that transcranial doppler-
187 documented early (<6 hours) recanalization of middle cerebral artery occlusion was
188 associated with the improved functional outcome despite the development of hemorrhagic
189 transformation, whereas late (>6 hours) recanalization was followed by increased rates of
190 symptomatic intracerebral hemorrhage” [35] .

191 The intra-arterial route of thrombolytic administration is associated with an increased rate of
192 HT compared with the intravenous route, although the predictive factors might be similar
193 (37). Among the factors that increase the risk of HT in intra-arterial thrombolysis are post-
194 procedure evidence of contrast extravasation on CT [37], a higher number of micro-catheter
195 injections (39), and a higher dose of heparin used during the procedure [39].

196 **4.1.7 Stroke Severity**

197 There is a strong relationship between the infarct volume and hemorrhagic transformation.
198 The National Institute of Health Stroke Scale (NIHSS) score has been shown to be a
199 significant predictor unit in assessing the infarct volume [15] and as at such the NIHSS
200 score serves as a rough guide in estimating stroke severity, and in predicting bleeding
201 transformation of acute ischemic stroke [13]. NIHSS score of zero means no stroke
202 symptoms, 1 to 4 means minor stroke, 5 to 15 means moderate stroke, 16 to 20 means
203 moderate or severe stroke, and 21 to 42 means severe stroke [40]. It has been shown that
204 patients with a NIHSS score less than 10 had less than 13% rate of HT in comparison with
205 patients who had NIHSS score greater than 15 having more than 50% rate of HT [41].
206 Findings from Yuan et al showed that stroke severity (baseline NIHSS score) was an
207 independent risk factor of hemorrhagic transformation of acute ischemic stroke [13].

208 **4.1.8 Hypertension**

209 The effect of hypertension on the risk of HT was documented in EPITHET (Echo-planar
210 Imaging Thrombolytic Evaluation Trial), a study of intravenous alteplase thrombolysis within
211 3 to 6 hour of stroke onset [42].

212 Factors significantly associated with increased risk of HT included a large infarct on diffusion
213 weighted imaging MRI at baseline and elevated systolic blood pressure 24 hours after
214 treatment [42]. High blood pressure has been related to intracranial hemorrhage after rtPA
215 for ischemic stroke in both experimental and clinical settings [43], and an association of
216 baseline systolic blood pressure with PH underscores the importance of thorough
217 management of blood pressure in patients who are given rtPA [14].

218 **4.1.9 Advanced MRI Parameters**

219 MRI is more sensitive than CT for detection of HT after acute ischaemic stroke, [44, 45]
220 especially with inclusion of the gradient echo sequence, which is highly accurate in detection
221 of blood products. Arnould et al, with use of 1.5T MRI, reported high accuracy of the gradient
222 echo sequence for detection of HT after thrombolytic treatment compared with CT and with
223 fluid-attenuated inversion recovery (FLAIR) and spin-echo MRI Sequences [44].

224 Multiple studies have reported the diagnostic performance of magnetic resonance imaging
225 (MRI) for prediction of hemorrhagic transformation in acute ischemic stroke [46–48].
226 Conventional MRI using FLAIR sequences, as well as advanced MRI protocols including
227 perfusion-weighted imaging (PWI) (dynamic susceptibility-weighted [T2-weighted (T2-W)])
228 imaging and dynamic contrast-enhanced [T1-weighted] imaging) and diffusion-weighted
229 imaging (DWI) have shown promising results. In particular, T2-W imaging can sensitively
230 reveal hemorrhagic events of a mild degree in ischemic stroke.

231 Suh et al discovered that hemorrhagic transformation of ischemic stroke is associated with
232 high permeability, hypoperfusion, low apparent diffusion coefficient (ADC), and FLAIR
233 hyperintensity [49]. They also demonstrated that high blood-brain barrier permeability and
234 low cerebral blood volume (CBV) derived from PWI were associated with hemorrhagic
235 transformation of ischemic stroke. It has been shown that MRI PWI offers several
236 advantages in the prediction of hemorrhagic transformation due to its high contrast-to-noise
237 ratio, ability to capture the entire spectrum of acute ischemic stroke from multiple small foci
238 to the larger vascular territory, and no ionizing radiation [49].

239 A meta-analysis demonstrated that presence of cerebral microbleeds and high cerebral
240 microbleeds burden on pretreatment MRI were independently associated with symptomatic
241 intracerebral hemorrhage in patients with acute ischemic stroke treated with intravenous
242 thrombolysis [50]. Another study reported that microbleeds on susceptibility-weighted
243 imaging (SWI) showed a significant association with hemorrhagic transformation [51].
244 Therefore, hemorrhagic transformation is also probably associated with the presence of
245 cerebral microbleed and high cerebral microbleeds burden.

246 **4.1.10 Others**

247 In patients not treated with alteplase, the only independent predictor of HT identified in a
248 prospective study was the detection of focal hypodensity on computed tomography (CT)
249 performed early (within five hours) after symptom onset [44]. The presence of focal
250 hypodensity was associated with subsequent HT in 77% of cases, and its absence predicted
251 the absence of HT in 94% of cases [44]. In the NINDS rt-PA trial using the Alberta Stroke
252 Programme Early CT Scale (ASPECTS) imaging tool, patients with an ASPECTS score of
253 seven or less (showing extensive hypoattenuation of the parenchyma) did not show a

254 significant increase in symptomatic intracerebral hemorrhage [45]. It should be noted that
255 hemorrhagic transformation of ischemic stroke is almost never seen in acute lacunar stroke.
256 This can be explained from the fact that Lacunar stroke occurs due to occlusion of a small
257 cerebral vessels that supply a small area in the brain [55].

258 5. PROGNOSIS

259 Hemorrhagic transformation of CVA has a worse outcome compared to ischemic CVA
260 without it. Some studies have been able to find an association between the subtypes of
261 hemorrhagic transformation and functional outcome. A study conducted by Van Kranendock
262 et al, revealed that more than half of patients(66%) studied with symptomatic intracranial
263 hemorrhages died [46]. An intracranial hemorrhage is considered symptomatic if the patient
264 had clinical deterioration resulting in an increase of less than 4 or more points on National
265 Institute of Health Stroke Scale (NIHSS) [35]. Patients with PH2 and HI2 were said to have
266 the worst functional outcome. Also a large volume infarct has been linked with worse
267 functional outcome [35].

268 5. CONCLUSION

269 This study elucidated risk factors associated with hemorrhagic transformation of acute
270 ischemic stroke, and its pathogenesis. We demonstrated that interplay of various factors was
271 involved in the hemorrhagic transformation of ischemic stroke. Although ischemic stroke is
272 known to have a high morbidity, this study has shown that hemorrhagic transformation
273 increases the morbidity and as well as mortality of patients who have ischemic stroke.
274

275 ACKNOWLEDGEMENTS

276
277 This research did not receive any specific grant from funding agencies in the public,
278 commercial, or not-for-profit sectors.
279

281 COMPETING INTERESTS

282
283 Authors have declared that no competing interests exist.
284

285 AUTHORS' CONTRIBUTIONS

286
287 Omotola Akinade, Gabriel Alugba, Chidinma Chukwudum, Alexsandra Urhi, Gibson
288 Anugwom designed the study, performed the statistical analysis, wrote the protocol, and
289 wrote the first draft of the manuscript and reviewed and made the necessary edits. Adewale
290 Mark Adedoyin, Obiamaka Pamela Okereke, Abimbola Eunice Arisoyin wrote the protocol,
291 managed the analyses of the study and wrote the first draft of the manuscript. Ojali Ruth
292 Unedu, Adeyinka Aladejare, Aduwa Obosakhi, Funmilola Babalola, Ayobami Adesuyi,
293 Favour David, Benedicta Kolajo managed the literature searches, wrote the first and second
294 draft of the manuscript. All authors read and approved the final manuscript.
295

296
297

298 REFERENCES

- 299 1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and
300 Stroke Statistics-2017 Update: A Report From the American Heart Association. *Circulation*.
301 2017;135(10):e146–603. DOI: 10.1161/CIR.0000000000000485

- 302 2. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart
303 Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.
304 *Circulation*. 2021;143(8):E254–743. DOI: 10.1161/CIR.0000000000000950
- 305 3. Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional,
306 and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the
307 Global Burden of Disease Study 2019. *Lancet Neurol*. 2021;20(10):1–26. DOI:
308 10.1016/s1474-4422(21)00252-0
- 309 4. Khan SU, Khan MZ, Khan MU, Khan MS, Mamas MA, Rashid M, et al. Clinical and
310 Economic Burden of Stroke Among Young, Midlife, and Older Adults in the United States,
311 2002-2017. *Mayo Clin proceedings Innov Qual outcomes*. 2021;5(2):431–41. DOI:
312 10.1016/j.mayocpiqo.2021.01.015
- 313 5. Lapchak PA. Hemorrhagic transformation following ischemic stroke: significance, causes,
314 and relationship to therapy and treatment. *Curr Neurol Neurosci Rep*. 2002;2(1):38–43. DOI:
315 10.1007/s11910-002-0051-0
- 316 6. Kim TJ, Lee JS, Park SH, Ko SB. Short-term glycemic variability and hemorrhagic
317 transformation after successful endovascular thrombectomy. *Transl Stroke Res*.
318 2021;12(6):968–75. DOI: 10.1007/s12975-021-00895-4
- 319 7. Boysen G. European Cooperative Acute Stroke Study (ECASS): (rt-PA-Thrombolysis in
320 acute stroke) study design and progress report. *Eur J Neurol*. 1995;1(3):213–9. DOI:
321 10.1111/j.1468-1331.1995.tb00074.x
- 322 8. Arboix A, Jiménez C, Massons J, Parra O, Besses C. Hematological disorders: a commonly
323 unrecognized cause of acute stroke. 2016;9(9):891–901. DOI:
324 10.1080/17474086.2016.1208555
- 325 9. Inzitari D, Giusti B, Nencini P, Gori AM, Nesi M, Palumbo V, et al. MMP9 variation after
326 thrombolysis is associated with hemorrhagic transformation of lesion and death. *Stroke*.
327 2013;44(10):2901–3. DOI: 10.1161/strokeaha.113.002274
- 328 10. Hirata Y, Kato N, Muraga K, Shindo A, Nakamura N, Matsuura K, et al. Cerebral
329 Microbleeds With Atrial Fibrillation After Ablation Therapy. *Front Cell Neurosci*. 2022;16.
330 DOI: 10.3389/fncel.2022.818288
- 331 11. D’Anna L, Filippidis FT, Harvey K, Marinescu M, Bentley P, Korompoki E, et al. Extent of
332 white matter lesion is associated with early hemorrhagic transformation in acute ischemic
333 stroke related to atrial fibrillation. *Brain Behav*. 2021;11(8). DOI: 10.1002/brb3.2250
- 334 12. Lin C, Pan H, Qiao Y, Huang P, Su J, Liu J. Fibrinogen Level Combined With Platelet Count
335 for Predicting Hemorrhagic Transformation in Acute Ischemic Stroke Patients Treated With
336 Mechanical Thrombectomy. *Front Neurol*. 2021;12. DOI: 10.3389/fneur.2021.716020
- 337 13. Ruan Y, Yuan C, Liu Y, Zeng Y, Cheng H, Cheng Q, et al. High fibrinogen-to-albumin ratio
338 is associated with hemorrhagic transformation in acute ischemic stroke patients. *Brain Behav*.
339 2021;11(1). DOI: 10.1002/brb3.1855
- 340 14. Yuan S, Li W, Hou C, Kang H, Ma Q, Ji X, et al. Serum Occludin Level Combined With
341 NIHSS Score Predicts Hemorrhage Transformation in Ischemic Stroke Patients With
342 Reperfusion. *Front Cell Neurosci*. 2021;15. DOI: 10.3389/fncel.2021.714171
- 343 15. Wei C, Liu J, Guo W, Jin Y, Song Q, Wang Y, et al. Development and Validation of a
344 Predictive Model for Spontaneous Hemorrhagic Transformation After Ischemic Stroke. *Front*
345 *Neurol*. 2021;12. DOI: 10.3389/fneur.2021.747026
- 346 16. Marsh EB, Llinas RH, Hillis AE, Gottesman RF. Hemorrhagic transformation in patients with
347 acute ischaemic stroke and an indication for anticoagulation. *Eur J Neurol*. 2013;20(6):962–7.

- 348 DOI: 10.1111/ene.12126
- 349 17. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk Factors for Intracranial
350 Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue
351 Plasminogen Activator. *Stroke*. 2012; DOI: 10.1161/STROKEAHA.112.665331
- 352 18. Berrouschot J, Röther J, Glahn J, Kucinski T, Fiehler J, Thomalla G. Outcome and severe
353 hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in
354 very old (> or =80 years) stroke patients. *Stroke*. 2005;36(11):2421–5. DOI:
355 10.1161/01.str.0000185696.73938.e0
- 356 19. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with
357 acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. *J Neurol*
358 *Neurosurg Psychiatry*. 2006;77(7):826–9. DOI: 10.1136/jnnp.2005.086595
- 359 20. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, et al. Matrix
360 metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after
361 thrombolysis in human stroke. *Circulation*. 2003;107(4):598–603. DOI:
362 10.1161/01.cir.0000046451.38849.90
- 363 21. Mosesson MW. Fibrinogen and fibrin structure and functions. *J Thromb Haemost*.
364 2005;3(8):1894–904. DOI: 10.1111/j.1538-7836.2005.01365.x
- 365 22. Wang R, Zeng J, Wang F, Zhuang X, Chen X, Miao J. Risk factors of hemorrhagic
366 transformation after intravenous thrombolysis with rt-PA in acute cerebral infarction. *QJM*.
367 2019;112(5):323–6. DOI: 10.1093/qjmed/hcy292
- 368 23. Yan S, Zhang X, Zhang R, Xu J, Lou M. Early Fibrinogen Depletion and Symptomatic
369 Intracranial Hemorrhage After Reperfusion Therapy. *Stroke*. 2019;50(10):2716–21. DOI:
370 10.1161/strokeaha.119.025711
- 371 24. Rodríguez-Yáñez M, Castellanos M, Blanco M, Millán M, Nombela F, Sobrino T, et al.
372 Micro- and macroalbuminuria predict hemorrhagic transformation in acute ischemic stroke.
373 *Neurology*. 2006;67(7):1172–7. DOI: 10.1212/01.wnl.0000238353.89194.08
- 374 25. Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, et al. Admission glucose level
375 and clinical outcomes in the NINDS rt-PA Stroke Trial. *Neurology*. 2002;59(5):669–74. DOI:
376 10.1212/wnl.59.5.669
- 377 26. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, et al. Cerebral
378 hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial.
379 *Neurology*. 2001;57(9):1603–10. DOI: 10.1212/wnl.57.9.1603
- 380 27. Poppe AY, Majumdar SR, Jeerakathil T, Ghali W, Buchan AM, Hill MD. Admission
381 Hyperglycemia Predicts a Worse Outcome in Stroke Patients Treated With Intravenous
382 Thrombolysis. *Diabetes Care*. 2009;32(4):617. DOI: 10.2337%2Fdc08-1754
- 383 28. Álvarez-Sabín J, Maisterra O, Santamarina E, Kase CS. Factors influencing haemorrhagic
384 transformation in ischaemic stroke. *Lancet Neurol*. 2013;12(7):689–705. DOI:
385 10.1016/s1474-4422(13)70055-3
- 386 29. Li W, Xing X, Wen C, Liu H. Risk factors and functional outcome were associated with
387 hemorrhagic transformation after mechanical thrombectomy for acute large vessel occlusion
388 stroke. *J Neurosurg Sci*. 2020; DOI: 10.23736/s0390-5616.20.05141-3
- 389 30. Tirschwell D. Intra-arterial prourokinase for acute ischemic stroke. *J Am Med Assoc*.
390 2000;283(16):2003–11. DOI: 10.1001/jama.282.21.2003
- 391 31. Broderick JP. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke.
392 The NINDS t-PA Stroke Study Group. *Stroke*. 1997;28(11):2109–18. DOI:
393 10.1161/01.str.28.11.2109

- 394 32. Diedler J, Ahmed N, Sykora M, Uyttenboogaart M, Overgaard K, Lijckx GJ, et al. Safety of
395 intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at
396 stroke onset. *Stroke*. 2010;41(2):288–94. DOI: 10.1161/strokeaha.109.559724
- 397 33. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in
398 acute cardioembolic stroke: a meta-analysis of randomized controlled trials. *Stroke*.
399 2007;38(2):423–30. DOI: 10.1161/01.str.0000254600.92975.1f
- 400 34. HP A, BH B, LJ K, J B, BB L, DL G, et al. Classification of subtype of acute ischemic stroke.
401 Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke
402 Treatment. *Stroke*. 1993;24(1):35–41. DOI: 10.1161/01.str.24.1.35
- 403 35. Hakim AM, Ryder-Cooke A, Melanson D. Sequential computerized tomographic appearance
404 of strokes. *Stroke*. 1983;14(6):893–7. DOI: 10.1161/01.str.14.6.893
- 405 36. Molina CA, Montaner J, Abilleira S, Ibarra B, Romero F, Arenillas JF, et al. Timing of
406 spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic
407 stroke. *Stroke*. 2001;32(5):1079–84. DOI: 10.1161/01.str.32.5.1079
- 408 37. Kidwell CS, Saver JL, Carneado J, Sayre J, Starkman S, Duckwiler G, et al. Predictors of
409 hemorrhagic transformation in patients receiving intra-arterial thrombolysis. *Stroke*.
410 2002;33(3):717–24. DOI: 10.1161/hs0302.104110
- 411 38. Yoon W, Seo JJ, Kim JK, Cho KH, Park JG, Kang HK. Contrast enhancement and contrast
412 extravasation on computed tomography after intra-arterial thrombolysis in patients with acute
413 ischemic stroke. *Stroke*. 2004;35(4):876–81. DOI: 10.1161/01.str.0000120726.69501.74
- 414 39. Khatri R, Khatri P, Khoury J, Broderick J, Carrozzella J, Tomsick T. Microcatheter contrast
415 injections during intra-arterial thrombolysis increase intracranial hemorrhage risk. *J*
416 *Neurointerv Surg* [Internet]. 2010 Jun [cited 2022 Jul 24];2(2):115–9. Available from:
417 <https://pubmed.ncbi.nlm.nih.gov/21990590/>
- 418 40. Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase
419 II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle
420 cerebral artery stroke. PROACT Investigators. *Prolyse in Acute Cerebral Thromboembolism*.
421 *Stroke*. 1998;29(1):4–11. DOI: 10.1161/01.str.29.1.4
- 422 41. Grönberg A, Henriksson I, Lindgren A. Accuracy of NIH Stroke Scale for diagnosing
423 aphasia. *Acta Neurol Scand*. 2021;143(4):375–82. DOI: 10.1111/ane.13388
- 424 42. Spronk E, Sykes G, Falcione S, Munsterman D, Joy T, Kamtchum-Tatuene J, et al.
425 Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation. *Front Neurol*.
426 2021 12:597. DOI: 10.3389/fneur.2021.661955
- 427 43. Butcher K, Christensen S, Parsons M, De Silva DA, Ebinger M, Levi C, et al.
428 Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation.
429 *Stroke*. 2010;41(1):72–7. DOI: 10.1161/strokeaha.109.563767
- 430 44. Larrue V, Von Kummer R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic
431 transformation in ischemic stroke patients treated with recombinant tissue plasminogen
432 activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
433 *Stroke*. 2001;32(2):438–41. DOI: 10.1161/01.str.32.2.438
- 434 45. Comparison of CT and three MR sequences for detecting and categorizing early (48 hours)
435 hemorrhagic transformation in hyperacute ischemic stroke - PubMed. 2004;25(6):939-44.
436 Available from: <https://pubmed.ncbi.nlm.nih.gov/15205127/>
- 437 46. Renou P, Sibon I, Tourdias T, Rouanet F, Rosso C, Galanaud D, et al. Reliability of the
438 ECASS radiological classification of postthrombolysis brain haemorrhage: a comparison of
439 CT and three MRI sequences. *Cerebrovasc Dis*. 2010;29(6):597–604. DOI:

440 10.1159/000312867
441 47. Kassner A, Liu F, Thornhill RE, Tomlinson G, Mikulis DJ. Prediction of hemorrhagic
442 transformation in acute ischemic stroke using texture analysis of postcontrast T1-weighted
443 MR images. *J Magn Reson Imaging*. 2009;30(5):933–41. DOI: 10.1002/jmri.21940
444 48. Jha R, Battey TWK, Pham L, Lorenzano S, Furie KL, Sheth KN, et al. Fluid-attenuated
445 inversion recovery hyperintensity correlates with matrix metalloproteinase-9 level and
446 hemorrhagic transformation in acute ischemic stroke. *Stroke*. 2014;45(4):1040–5. DOI:
447 10.1161/strokeaha.113.004627
448 49. Guo G, Yang Y, Yang W. Validation of hyperintense middle cerebral artery sign in acute
449 ischemic stroke: Comparison between magnetic resonance imaging and angiography☆.
450 *Neural Regen Res*. 2012;7(3):229. DOI: 10.3969%2Fj.issn.1673-5374.2012.03.013
451 50. Suh CH, Jung SC, Cho SJ, Woo DC, Oh WY, Lee JG, et al. MRI for prediction of
452 hemorrhagic transformation in acute ischemic stroke: a systematic review and meta-analysis.
453 *Acta Radiol*. 2020;61(7):964–72. DOI: 10.1177/0284185119887593
454 51. Tsivgoulis G, Zand R, Katsanos AH, Turc G, Nolte CH, Jung S, et al. Risk of symptomatic
455 intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke
456 and high cerebral microbleed burden ameta-analysis. *JAMA Neurol*. 2016;73(6):675–83.
457 DOI: 10.1001/jamaneurol.2016.0292
458 52. Huang P, Chen CH, Lin WC, Lin RT, Khor GT, Liu CK. Clinical applications of
459 susceptibility weighted imaging in patients with major stroke. *J Neurol*. 2012;259(7):1426–
460 32. DOI: 10.1007/s00415-011-6369-2
461 53. Toni D, Fiorelli M, Bastianello S, Sacchetti ML, Sette G, Argentino C, et al. Hemorrhagic
462 transformation of brain infarct: predictability in the first 5 hours from stroke onset and
463 influence on clinical outcome. *Neurology*. 1996;46(2):341–5. DOI: 10.1212/wnl.46.2.341
464 54. Demchuk AM, Hill MD, Barber PA, Silver B, Patel SC, Levine SR. Importance of early
465 ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study.
466 *Stroke* [Internet]. 2005 Oct [cited 2022 Jul 24];36(10):2110–5. Available from:
467 <https://pubmed.ncbi.nlm.nih.gov/16166579/>
468 55. Rudilosso S, Rodríguez-Vázquez A, Urra X, Arboix A. The Potential Impact of
469 Neuroimaging and Translational Research on the Clinical Management of Lacunar Stroke. *Int*
470 *J Mol Sci*. 2022;23(3). DOI: 10.3390/ijms23031497
471
472